Home UVA Health research leads to development of new Parkinson’s drug
Virginia

UVA Health research leads to development of new Parkinson’s drug

Chris Graham
cognitive ability burnout brain
Photo: © Viktor/Adobe Stock

More than 11 million people around the world live with Parkinson’s, an age-related neurological condition that causes tremors, difficulty moving and can come with symptoms such as fatigue, insomnia, memory loss and impaired ability to concentrate.

The FDA has approved a new Parkinson’s drug that was based on research by UVA Health scientists. 

The drug tavapadon, now branded Juvmo, was pioneered by UVA School of Medicine Professor Richard B. Mailman.

Xuemei Huang, chair of the Department of Neurology, also played a key role in the first successful clinical trial with a drug of this class.

Finding better ways to treat complex diseases is a major mission of UVA’s Paul and Diane Manning Institute of Biotechnology.

The institute aims to more quickly translate UVA’s cutting-edge science into new drugs and treatments to benefit patients across Virginia and beyond.

Early drugs in the class, called D1 agonists, could only be injected, but Juvmo is taken as a pill once per day.

The current gold-standard Parkinson’s medication, levodopa, requires multiple doses per day at increasingly frequent intervals as the disease progresses.

“The gold standard drug for nearly 60 years has been levodopa, available in many forms. Unfortunately, it requires some of the very nerve cells that are dying in Parkinson’s. This means it is harder to use and less effective with time,” Mailman said.

“We figured out the specific mechanism that made levodopa effective, and developed the first drug that could turn on that mechanism. Juvmo itself was made by a brilliant chemist and team who made a similar drug that could be given as a pill only once or twice a day,” Mailman said.

Parkinson’s is driven by the gradual death of nerve cells that make and use the hormone dopamine. No way has been found to stop this degeneration. Juvmo can selectively activate D1 dopamine receptors in the brain, providing relief from some of the disease’s motor symptoms.

The drug’s unique way of working means it may cause fewer side effects than levodopa. While Juvmo can be combined with levodopa, Juvmo also may serve as an important new option for patients for whom the symptoms cannot be optimally controlled.

“Because the target of Juvmo does not degenerate in Parkinson’s disease, the hope is that it will smooth out current problems and also allow symptomatic relief to continue for much longer periods.” Huang said. “Indeed, our own research has suggested that there is hope that it might be helpful for patients in very late stages of PD for whom we do not have effective therapy. With the availability of Juvmo, these ideas can be tested.”

Juvmo will be marketed by the drug company AbbVie and is expected to become available in October.

 

Support AFP

Newsletter

Featured Video

 

 




Chris Graham

Chris Graham

Chris Graham is the founder and editor of Augusta Free Press. A 1994 alum of the University of Virginia, Chris is the author and co-author of seven books, including Poverty of Imagination, a memoir published in 2019. For his commentaries on news, sports and politics, go to his YouTube page, TikTok, BlueSky, or subscribe to his Street Knowledge podcast. Email Chris at [email protected]. Support AFP by signing up for our newsletter and/or powering our work with a one-time or monthly contribution.

Latest News

National Christmas Tree
Local

Highland County red spruce selected to serve as National Christmas Tree

school bus arm
Local

Albemarle County schools closed because of another major administrative screwup

More than 500 people hired in the past three years to work for Albemarle County Public Schools were not checked against the Child Protective Services Central Registry.

newspaper online news AFP mobile phone newsfeed
Local

AFP needs to do more: Just warning you, we’re going to ask for your help to get there

For years, OK, dating back to 2002, when we launched AFP, our thinking has been, survive, but now that we’ve jumped in headfirst into building and fleshing out a new model for sustainability, I’m starting to think about doing more than just living to see another day.

uva central grounds
Football, Go 'Hoos

Conservative alums lead the fight to hold UVA accountable for the failures of Nov. 13

mobile games casino phone computer
Politics, Virginia

State AGs pushing Trump FCC to take real steps to get rid of annoying robocalls

uva basketball thijs de ridder
Basketball, Go 'Hoos

UVA Basketball: NBA-like early schedule, tempo, defense, Gertrude/de Ridder

pit bull dog
Football, Go 'Hoos

UVA Football: Elliott, prodded by the media, heaps the praise on Solomon Beebe